• Multiple clinical milestones achieved including the first proof-of-concept for DMT-based therapies from a blinded placebo-controlled study • Preliminary findings from SPL028 Phase I clinical
What You Should Know: Texas Department of State Health Services (TX DSHS) has partnered with SAS to develop new public health dashboards for tracking influenza
What You Should Know: Gleamer, a Paris, France-based European manufacturer in AI-powered solutions for medical imaging raises €27M ($29.4M USD) in Series B funding led
What You Should Know: Virgin Pulse and Headspace expand their relationship to make it easier for employers and health plans to provide high-quality, affordable mental
Dive Brief: A former DePuy Synthes sales representative and team lead was arrested this week for allegedly defrauding a Boston area hospital and lying to
Dive Brief: Teleflex’s recall of its Arrow Endurance Extended Dwell Peripheral Catheter System was categorized by the U.S. Food and Drug Administration as a Class
Name: Kai Zhu New title: Invacare Senior Vice President and CFO Previous title: Invacare Vice President of Finance, EMEA Invacare has named Kai Zhu as
Lobbying groups representing the medtech industry are pushing back on proposed limits to ethylene oxide emissions in comments submitted to the Environmental Protection Agency, claiming the
Introduction of Psychedelics to Western Culture Since the dawn of the industrial revolution, Western culture has taken a mixed approach to handling consumption of psychoactive
TerrAscend Closes on Second Tranche of Private Placements for Total Aggregate Proceeds of US$20.5 Million TORONTO, June 28, 2023 (GLOBE NEWSWIRE) — TerrAscend Corp. (“TerrAscend”